Alnylam Pharmaceuticals, Inc. (ALNY) financial statements (2020 and earlier)

Company profile

Business Address 675 WEST KENDALL STREET
CAMBRIDGE, MA 02142
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,5361,7211,9271,2451,0841,2371,448
Cash and cash equivalents5479231,136725420317361
Short-term investments9897987915206649201,086
Restricted cash and investments00000  
Receivables434831341933
Inventory, net of allowances, customer advances and progress billings565541322411 
Inventory565541322411 
Other undisclosed current assets80746581739152
Total current assets:1,7161,8972,0641,3921,2011,3421,503
Noncurrent Assets
Operating lease, right-of-use asset221223  
Property, plant and equipment425396372342321273228
Restricted cash and investments15154847454545
Other noncurrent assets181010991614
Other undisclosed noncurrent assets  223224   
Total noncurrent assets:679644653622374334287
TOTAL ASSETS:2,3952,5422,7162,0141,5751,6761,789
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities247217210130172115102
Accounts payable50397123602212
Accrued liabilities1971781391071139490
Deferred revenue78107  
Debt2828     
Deferred rent credit    433
Contract with customer, liability893339
Other undisclosed current liabilities  2917   
Total current liabilities:353353329149179122114
Noncurrent Liabilities
Long-term debt and lease obligation2762763030303030
Long-term debt, excluding current maturities  3030303030
Operating lease, liability276276  
Liabilities, other than long-term debt3283053236634625
Deferred revenue318296  
Contract with customer, liability3140025
Deferred rent credit    584016
Other liabilities99105544
Other undisclosed noncurrent liabilities  277282   
Total noncurrent liabilities:604582631318937655
Total liabilities:956935959467273198169
Stockholders' equity
Stockholders' equity attributable to parent1,4391,6071,7571,5471,3021,4781,621
Common stock1111111
Additional paid in capital5,2015,0915,0344,6024,1754,1404,038
Accumulated other comprehensive loss(37)(34)(36)(33)(33)(33)(34)
Accumulated deficit(3,727)(3,451)(3,242)(3,023)(2,841)(2,630)(2,384)
Total stockholders' equity:1,4391,6071,7571,5471,3021,4781,621
TOTAL LIABILITIES AND EQUITY:2,3952,5422,7162,0141,5751,6761,789

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues7270453321230
Cost of revenue
(Cost of Goods and Services Sold)
(12)(5)(4)(3)(2)(0) 
Gross profit:6065403019230
Operating expenses(358)(281)(277)(219)(240)(256)(222)
Operating loss:(298)(216)(236)(189)(220)(255)(192)
Nonoperating income21718891029
Investment income, nonoperating710981176
Other nonoperating income (expense)14(3)(0)0(1)32
Other undisclosed loss from continuing operations before equity method investments, income taxes(1)      
Loss from continuing operations before equity method investments, income taxes:(277)(209)(219)(181)(211)(245)(163)
Other undisclosed income from continuing operations before income taxes1      
Loss from continuing operations before income taxes:(277)(209)(219)(181)(211)(245)(163)
Income tax expense (benefit)00(1)(1)(0)(0)(0)
Net loss available to common stockholders, diluted:(276)(209)(219)(182)(211)(245)(164)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(276)(209)(219)(182)(211)(245)(164)
Other comprehensive income (loss)(2)1(3)0   
Other undisclosed comprehensive income    1  
Comprehensive loss:(278)(207)(222)(182)(210)(245)(164)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    (1)01
Comprehensive loss, net of tax, attributable to parent:(278)(207)(222)(182)(211)(245)(163)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: